Enanta Pharmaceuticals reported $-32147000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Anika Therapeutics ANIK:US $ -3.28M 0.42M
Arrowhead Research ARWR:US $ -72.05M 116.41M
Biogen BIIB:US $ 874.8M 28.6M
Clovis Oncology CLVS:US $ -71.37M 11.08M
Enanta Pharmaceuticals ENTA:US $ -32.15M 1.44M
Halozyme Therapeutics HALO:US $ 30.01M 51.62M
Insmed INSM:US $ -95144000 908K
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Marinus Pharmaceuticals MRNS:US $ -39.43M 20.07M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NOVN:VX SF 4129M 217M
Novavax NVAX:US $ -509.07M 715.14M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Vital Therapies VTL:US $ -21.9M 1.09M